Novo Nordisk Captured 80% of New Oral GLP-1 Prescriptions in Q3 2026
Novo Nordisk captured 80% of new oral GLP-1 weight-loss prescriptions during the third quarter of 2026, moving toward a volume-driven business model.
Despite this commercial traction, shares of the Danish pharmaceutical giant remain 70% below their previous all-time highs following a series of supply chain constraints and increased competition.
The pharmaceutical landscape shifted significantly after Novo Nordisk struggled to maintain inventory levels for its Wegovy shot, a misstep that allowed rival Eli Lilly to gain substantial market share. Investors have since reacted with pessimism, driving the stock’s price-to-earnings ratio down to approximately 10x, a sharp decline from its five-year average of 23x, according to The Motley Fool.
Novo Nordisk is currently transitioning toward a volume-driven model, which requires lowering drug prices to capture more patient segments. This shift has created immediate pressure on top-line revenue, though management recently raised its full-year 2026 guidance. The company now anticipates adjusted sales and operating profit to range between a 2% decline and 2% growth, an improvement from previous projections of a 3% contraction, Seeking Alpha reported.
| Metric | Current Standing/Guidance |
|---|---|
| 2026 Free Cash Flow Guidance | DKK 60–70 billion |
| Dividend Yield | 4.5% |
| Price-to-Sales Ratio | 3.3x |
| Industry Avg. Dividend Yield | 1.3% |
Competition within the GLP-1 space continues to intensify. The 2032 expiration of semaglutide patents looms as a long-term threat to the company’s primary revenue stream. To counter this, management plans to introduce at least five multi-blockbuster products by 2030, targeting expansion into cardiovascular and liver disease treatments, as noted by Seeking Alpha.
The company’s dividend profile has become a focal point for aggressive investors. With a payout ratio of roughly 33% and a yield of 4.5%, Novo Nordisk offers a significantly higher return than the 1.3% pharmaceutical industry average.
Novo Nordisk traces its origins to two Danish insulin pioneers founded in the 1920s: Nordisk Insulin Laboratorium and Novo Terapeutisk Laboratorium. The latter introduced the world’s first insulin pen device, Novopen, in 1985. The modern corporation was created in 1989 through their merger, at which point the combined entity employed 7,350 people. By 2023, its market capitalization had exceeded the GDP of Denmark, making it the highest valued company in Europe.
Investors assessing the current valuation should consider the company’s price-to-book ratio of 5.2x, which sits well below its long-term average of 15x. As Novo Nordisk executes its plan, the market will monitor whether the volume-driven approach can effectively offset the compressed margins inherent in lower price points. The company expects these efforts to yield over DKK 150 billion in combined pipeline sales by 2035.